Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I study of SAIL66 in CLDN6-positive advanced or metastatic solid tumors
jRCT2031220588Phase 1Completed
- Sponsor
- Chugai Pharmaceutical Co., Ltd.
- Start
- Apr 2023
- Modality
- T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Trispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 2
01
Overview
Phase 1, open-label, single-arm trial of SAIL66 in Nonhematologic neoplasms, sponsored by Chugai Pharmaceutical Co., Ltd. Primary endpoints: Safety and tolerability and Efficacy. Started Apr 2023; status: completed.
02
Drugs
SAIL66
03
Conditions
Nonhematologic neoplasms
Beyond the preview
Go deeper on jRCT2031220588.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031220588.